Notícias e Atividades da Outlook Therapeutics

Outlook Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Outlook Therapeutics é uma empresa listada sob o símbolo OTLK (US).

Veja o organograma con seus 14 executivos principais

Biografias mais buscadas da Outlook Therapeutics

• Lawrence Kenyon, Chief Executive Officer and Director
• Randy Thurman, Chairman of the Board
• Julian Gangolli, Director

Recentes movimentos de executivos em Outlook Therapeutics

• Russell Trenary, President, Chief Executive Officer and Director, deixou a Companhia  (Notícia publicada em 4 de dezembro de 2024).
• Lawrence Kenyon antes Chief Financial Officer and Director, agora é Chief Executive Officer and Director  (Notícia publicada em 4 de dezembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Outlook Therapeutics.

Outlook Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Outlook Therapeutics

• Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) - Outlook Therapeutics, Inc.
• Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital - Outlook Therapeutics, Inc.
• Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration - Outlook Therapeutics, Inc.
• Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at Two Upcoming Investor Conferences - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at Two Upcoming Investor Conferences - Outlook Therapeutics, Inc.
• Press Releases - Outlook Therapeutics, Inc.
• Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1 - Outlook Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Outlook Therapeutics

• Outlook Therapeutics na Wikipedia, Google News e Yahoo Finance
• Outlook Therapeutics na LinkedIn, Twitter e YouTube